Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis

[1]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[2]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[3]  G. Sica,et al.  Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer , 2013, Molecular Cancer Therapeutics.

[4]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[5]  A. Martínez-Torteya,et al.  SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis , 2013, PloS one.

[6]  R. Moriggl,et al.  Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma , 2013, British Journal of Cancer.

[7]  T. Stinchcombe,et al.  KRAS mutation: should we test for it, and does it matter? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Kamińska,et al.  Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity. , 2013, Experimental cell research.

[9]  G. K. Gray,et al.  Activation of the NF-κB Pathway by the STAT3 Inhibitor JSI-124 in Human Glioblastoma Cells , 2013, Molecular Cancer Research.

[10]  John V Heymach,et al.  CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. , 2013, Cancer research.

[11]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[12]  J. Fagin,et al.  STAT3 negatively regulates thyroid tumorigenesis , 2012, Proceedings of the National Academy of Sciences.

[13]  N. Neamati,et al.  Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. , 2012, Journal of medicinal chemistry.

[14]  Kenji Mizuguchi,et al.  Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. , 2012, Cancer research.

[15]  J. Minna,et al.  Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer , 2012, International journal of cancer.

[16]  Jongdae Lee,et al.  Signal Transducer and Activator of Transcription 3 (STAT3) Protein Suppresses Adenoma-to-carcinoma Transition in Apcmin/+ Mice via Regulation of Snail-1 (SNAI) Protein Stability* , 2012, The Journal of Biological Chemistry.

[17]  E. Galun,et al.  Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis , 2012, Clinical and Translational Oncology.

[18]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[19]  Brian Bierie,et al.  Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. , 2011, The Journal of clinical investigation.

[20]  Helen H. W. Chen,et al.  Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells. , 2011, Molecular endocrinology.

[21]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[22]  M. Serrano,et al.  Nature Genetics Advance Online Publication the Stress Kinase Mkk7 Couples Oncogenic Stress to P53 Stability and Tumor Suppression , 2022 .

[23]  Christof Fellmann,et al.  Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.

[24]  Je-in Youn,et al.  The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity , 2010, European journal of immunology.

[25]  Akihiko Yoshizawa,et al.  A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors , 2010, The American journal of surgical pathology.

[26]  E. Casanova,et al.  Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. , 2010, Gastroenterology.

[27]  J. Nevins,et al.  Age- and sex-specific genomic profiles in non-small cell lung cancer. , 2010, JAMA.

[28]  Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription‐3 with epidermal growth factor receptor blockade in lung cancer , 2009, International journal of cancer.

[29]  D. Levy,et al.  Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation , 2009, Science.

[30]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[31]  Hua Yu,et al.  Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.

[32]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[33]  L. Kenner,et al.  The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. , 2009, Frontiers in bioscience.

[34]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[35]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[36]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[37]  D. Louis,et al.  Deregulation of a STAT3–Interleukin 8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness , 2008, The Journal of Neuroscience.

[38]  David E Levy,et al.  Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.

[39]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[40]  Yan Liu,et al.  Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. , 2007, Molecular biology of the cell.

[41]  Z. Tian,et al.  Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice , 2007, BMC Cancer.

[42]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[43]  L. Mao,et al.  Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. , 2007, International journal of oncology.

[44]  D. Gingras,et al.  Membrane-Type 1 Matrix Metalloproteinase Stimulates Cell Migration through Epidermal Growth Factor Receptor Transactivation , 2007, Molecular Cancer Research.

[45]  Antonio Porro.  In vivo dual cross-linking chromatin immunoprecipitation: detecting chromatin proteins not directly bound to DNA (PROT29) , 2007 .

[46]  M. Kasper,et al.  Efficient manipulation of Hedgehog/GLI signaling using retroviral expression systems. , 2007, Methods in molecular biology.

[47]  F. Luppia,et al.  Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation , 2007 .

[48]  A. Zlotnik,et al.  The chemokine and chemokine receptor superfamilies and their molecular evolution , 2006, Genome Biology.

[49]  A. Baldwin,et al.  Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. , 2006, Oncogene.

[50]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[51]  G. Bepler,et al.  Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[52]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Levy,et al.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.

[54]  J. Mesirov,et al.  An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.

[55]  P. Woll,et al.  Interleukin-8/CXCL8 is a growth factor for human lung cancer cells , 2004, British Journal of Cancer.

[56]  F. Peale,et al.  VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis , 2004, The EMBO journal.

[57]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[58]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[59]  J. Turkson,et al.  Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells , 2003, Oncogene.

[60]  L. Benjamin,et al.  Angiogenesis: Tumorigenesis and the angiogenic switch , 2003, Nature Reviews Cancer.

[61]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Wenzheng Zhang,et al.  Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. , 2002, The Biochemical journal.

[63]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[64]  A. Richmond.  Nf-kappa B, chemokine gene transcription and tumour growth. , 2002, Nature reviews. Immunology.

[65]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[66]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[67]  V. Poli,et al.  Essential Role of STAT3 in the Control of the Acute-Phase Response as Revealed by Inducible Gene Activation in the Liver , 2001, Molecular and Cellular Biology.

[68]  Gabriella,et al.  Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. , 2001, Molecular and cellular biology.

[69]  G. Fuller,et al.  Interleukin 1β inhibits interleukin 6–mediated rat γ fibrinogen gene expression , 2000 .

[70]  G. Fuller,et al.  Interleukin 1beta inhibits interleukin 6-mediated rat gamma fibrinogen gene expression. , 2000, Blood.

[71]  M. Ward,et al.  Interleukin 8: an autocrine growth factor for malignant mesothelioma. , 1999, Cancer research.

[72]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[73]  A. Manning,et al.  Interleukin-4 Suppression of Tumor Necrosis Factor α-stimulated E-selectin Gene Transcription Is Mediated by STAT6 Antagonism of NF-κB* , 1997, The Journal of Biological Chemistry.

[74]  A. Manning,et al.  Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-kappaB. , 1997, The Journal of biological chemistry.